Currently, there are a handful of FDA‐approved ICIs targeting the CTLA‐4 and PD‐1/PD‐L1 axes in various cancers, with several novel mAbs currently being explored for clinical efficacy (Figure 2, Table 1). The gene discussed is PDCD1; the disease is cancer.